CpG oligonucleotides induce the differentiation of CD4 +Th17 cells by triggering plasmacytoid dendritic cells in adoptively cell transfer immunotherapy

Immunology Letters

Volumn 142, Issue 1-2, 2012, Pages 55-63

  Xu, Lin ^a   Wang, Chunhong ^b   Zhou, Ya ^a   Ren, Tao ^c   Wen, Zhenke ^d  

^a ZUNYI MEDICAL UNIVERSITY   (China)

^b Qingdao Chest Hospital   (China)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

CpG oligonucleotide; Plasmacytoid dendritic cell; Th17 cell; Tumor infiltrating lymphocyte

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL STIMULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; TH17 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CPG ISLANDS; DENDRITIC CELLS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; TH17 CELLS;

EID: 84862784059     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.12.006     Document Type: Article

References (28)

1. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M.D., Sato Y., Ronaghy A., et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997, 3:849-854.
2. Kraft A.R., Krux F., Schimmer S., Ohlen C., Greenberg P.D., Dittmer U. CpG oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection. Blood 2007, 109:2982-2984.
3. Murad Y.M., Clay T.M. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs 2009, 23:361-375.
4. Chaudhry U.I., Kingham T.P., Plitas G., Katz S.C., Raab J.R., DeMatteo R.P. Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth. Cancer Res 2006, 66:497-504.
5. Mangsbo S.M., Sandin L.C., Anger K., Korman A.J., Loskog A., Tötterman T.H. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010, 33:225-235.
6. Karbach J., Gnjatic S., Bender A., Neumann A., Weidmann E., Yuan J., et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int J Cancer 2010, 126:909-918.
7. Dudley M.E., Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003, 3:666-675.
8. Coccoris M., Straetemans T., Govers C., Lamers C., Sleijfer S., Debets R. T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies. Expert Opin Biol Ther 2010, 10:547-562.
9. Cartellieri M., Bachmann M., Feldmann A., Bippes C., Stamova S., Wehner R., et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol 2010, 2010:956304.
10. La Rosa C., Wang Z., Lacey S.F., Lalimarmo M.M., Krishnan A., Longmate J., et al. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. Exp Hematol 2006, 34:497-507.
11. Ren T., Wen Z.K., Liu Z.M., Qian C., Liang Y.J., Jin M.L., et al. Targeting Toll-like receptor 9 with CpG oligodeoxynucleotides enhances antitumor responses of peripheral blood mononuclear cells from human lung cancer patients. Cancer Invest 2008, 26:448-455.
12. Xu L., Wang C., Wen Z., Zhou Y., Liu Z., Liang Y., et al. CpG oligodeoxynucleotides enhance the efficacy of adoptive cell transfer using tumor infiltrating lymphocytes by modifying the Th1 polarization and local infiltration of Th17 cells. Clin Dev Immunol 2010, 2010:410893.
13. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8:299-308.
14. Lee J.J., Chang Y.L., Lai W.L., Ko J.Y., Kuo M.Y., Chiang C.P., et al. Increased prevalence of interleukin-17-producing CD4(+) tumor infiltrating lymphocytes in human oral squamous cell carcinoma. Head Neck 2011, 33:1301-1308.
15. Wainwright D.A., Sengupta S., Han Y., Ulasov I.V., Lesniak M.S. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One 2010, 5:e15390.
16. Miyabayashi T., Kagamu H., Koshio J., Ichikawa K., Baba J., Watanabe S., et al. Vaccination with CD133(+) melanoma induces specific Th17 and Th1 cell-mediated antitumor reactivity against parental tumor. Cancer Immunol Immunother 2011, 60:1597-1608.
17. Ankathatti Munegowda M., Deng Y., Mulligan S.J., Xiang J. Th17 and Th17-stimulated CD8(+) T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol Immunother 2011, 60:1473-1484.
18. Kryczek I., Wei S., Szeliga W., Vatan L., Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009, 114:357-359.
19. Muranski P., Boni A., Antony P.A., Cassard L., Irvine K.R., Kaiser A., et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112:362-373.
20. +T cell function and poor prognosis of breast cancer. Clin Immunol 2010, 135:466-475.
21. Yu C.F., Peng W.M., Oldenburg J., Hoch J., Bieber T., Limmer A., et al. Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation. J Immunol 2010, 184:1159-1167.
22. Isaksson M., Ardesjö B., Rönnblom L., Kämpe O., Lassmann H., Eloranta M.L., et al. Plasmacytoid DC promote priming of autoimmune Th17 cells and EAE. Eur J Immunol 2009, 39:2925-2935.
23. Gautreau L., Chabannes D., Heslan M., Josien R. Modulation of regulatory T cell-Th17 balance by plasmacytoid dendritic cells. J Leukoc Biol 2011, 90:521-527.
24. Koenen H.J., Smeets R.L., Vink P.M., van Rijssen E., Boots A.M., Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008, 112:2340-2352.
25. Weaver C.T., Hatton R.D., Mangan P.R., Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007, 5:821-852.
26. Bettelli E., Korn T., Kuchroo V.K. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007, 19:652-657.
27. Perrot I., Blanchard D., Freymond N., Isaac S., Guibert B., Pachéco Y., et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 2007, 178:2763-2769.
28. Wilke C.M., Kryczek I., Zou W. Antigen-presenting cell (APC) subsets in ovarian cancer. Int Rev Immunol 2011, 30:120-126.